Results 91 to 100 of about 29,210 (297)

Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio‐Oncology

European Journal of Heart Failure, EarlyView.
Specific characteristics of HFpEF universal definition in cancer patients. Abstract Heart failure with preserved ejection fraction (HFpEF) is increasingly recognized in cancer patients and survivors, yet it remains underdiagnosed and its epidemiology largely unknown.
Kalliopi Keramida, Teresa Lopez‐Fernandez, Markus S. Anker, Mark C. Petrie, Pietro Ameri, Lisa J. Anderson, Jutta Bergler‐Klein, Anita Deswal, Dimitrios Farmakis, Borja Ibañez, Carolyn S.P. Lam, Ninian N. Lang, Alexander R. Lyon, Mariana Mirabel, Brenda Moura, Walter J. Paulus, Amina Rakisheva, Gianluigi Savarese, Michele Senni, Carlo Gabriele Tocchetti, Marco Metra, Gerasimos Filippatos   +21 more
wiley   +1 more source

Dialog between mantle cell lymphoma cells and lymphoma-associated macrophages underlies ibrutinib resistance

Journal of Advanced Research
Introduction: Patients with mantle cell lymphoma (MCL) frequently develop resistance to ibrutinib. Lymphoma-associated macrophages (LAMs) may play a causal role in this resistance but remain underexplored in current literature.
Xiaoqing Sun, Caiqin Wang, Jianghua Cao, Jing Li, Gang Ma, Xianqiu Wu, Peng Sun, Yu Wang, Jiajia Huang, Robert Peter Gale, Zhiming Li   +10 more
doaj   +1 more source

Emerging Frontiers in Food Allergy Treatment: Progress, Challenges, and Prospects

Food Frontiers, EarlyView.
Food allergy is a rising global health concern with limited treatment options beyond allergen avoidance and emergency care. This review explores the evolving therapeutic landscape, highlighting advances in allergen immunotherapy, biologics such as monoclonal antibodies, and emerging vaccine‐based approaches.
Ayesha Zahid, Hazrat Ismail, Madiha Ajaz, Abdul Qadeer   +3 more
wiley   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation

Leukemia, 2023
Chronic lymphocytic leukemia (CLL) cells upregulate Bcl-2 proteins within the lymph node (LN) microenvironment. Signaling via B-cell receptor, Toll-like receptors and CD40 collectively reduce sensitivity to the BCL-2 inhibitor venetoclax.
K. Kielbassa, M. Haselager, Danique J. C. Bax, Bianca F. van Driel, J. Dubois, M. Levin, S. Kersting, R. Svanberg, C. Niemann, A. Kater, E. Eldering   +10 more
semanticscholar   +1 more source

Navigating Solute Carrier Transporters—A Comprehensive Review of Functionalized Small Molecule Probes for Target Identification and Characterization

Medicinal Research Reviews, EarlyView.
ABSTRACT Solute carrier transporters (SLCs) are integral membrane proteins that play pivotal roles in maintaining cellular homeostasis by mediating the transport of a diverse range of substrates across cell membranes. With their involvement in fundamental physiological processes such as nutrient uptake, neurotransmitter signaling, and drug transport ...
Majlen A. Dilweg, Tracie Widjaja, Adriaan P. IJzerman, Daan van der Es   +3 more
wiley   +1 more source

A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL

Blood Advances, 2022
Key Points • Patients with DLBCL Richter transformation of CLL have a poor prognosis, especially if they have had prior BTKi exposure.• Nivolumab and ibrutinib combination therapy is a safe and potential treatment option in patients with DLBCL Richter ...
N. Jain, J. Senapati, B. Thakral, A. Ferrajoli, P. Thompson, J. Burger, Sreyashi Basu, T. Kadia, N. Daver, G. Borthakur, M. Konopleva, N. Pemmaraju, E. Parry, Catherine J. Wu, J. Khoury, C. Bueso-Ramos, Naveen Garg, Xuemei Wang, W. Lopez, A. Ayala, S. O'brien, H. Kantarjian, M. Keating, J. Allison, Padmanee Sharma, W. Wierda   +25 more
semanticscholar   +1 more source

Comparative Analysis of Isavuconazole DDIs With Other Azole Antifungal Drugs and PBPK Model‐Informed Dosing Recommendations for Anticancer Drugs

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Isavuconazole is a broad‐spectrum triazole approved for the treatment of invasive aspergillosis or mucormycosis in adults and children aged ≥ 1 year. Current prescribing information lacks guidance regarding the co‐administration of isavuconazole with anticancer drugs–limited by the availability of clinical drug–drug interaction (DDI) data in ...
Theunis C. Goosen, Xiaofeng Wu, Jian Lin, Narayan Cheruvu, Susan R. Raber, Maria Lavinea Novis de Figueiredo, Manthena V. S. Varma   +6 more
wiley   +1 more source

Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions

Haematologica, 2019
While efficient at treating B-cell malignancies, Bruton tyrosine kinase (BTK) inhibitors are consistently reported to increase the risk of bleeding. Analyzing platelet aggregation response to collagen in platelet-rich plasma allowed us to identify two ...
Jennifer Series, Cédric Garcia, Marie Levade, Julien Viaud, Pierre Sié, Loïc Ysebaert, Bernard Payrastre   +6 more
doaj   +1 more source

Ibrutinib combinations in CLL therapy: scientific rationale and clinical results

Blood Cancer Journal, 2021
Ibrutinib has revolutionized the treatment of chronic lymphocytic leukemia (CLL). This drug irreversibly inhibits Bruton tyrosine kinase (BTK) by covalently binding to the C481 residue in the BTK kinase domain.
Natalia Timofeeva, Varsha Gandhi
doaj   +1 more source